HILLSIDE, N.J., May 31 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc.'s wholly-owned subsidiary, InB:Paxis Pharmaceuticals, Inc., a premier manufacturer of naturally derived taxanes for the pharmaceutical industry, today announced the execution of a supply agreement with a European generics manufacturing company with extensive sales, marketing, and distribution channels in the European Community, Eastern Europe, the United Kingdom and the United States. The agreement provides for minimum purchases during the first year of at least $2.4 million of InB:Paxis’ API product.
Rodney McKeever, Vice President of Operations and General Manager of InB:Paxis stated “We are pleased to have established a strong and effective working relationship with this important, new customer. During the past year we have been working together to satisfy the regulatory requirements of the European, U.K. and U.S. markets to be covered by this agreement and are now poised to support our customer’s sales in these important markets.”
About InB:Paxis Pharmaceuticals, Inc.
InB:Paxis Pharmaceuticals, Inc. is a US-based premier producer of naturally-derived taxanes for the pharmaceutical industry. InB:Paxis currently manages the cultivation, manufacturing and distribution of paclitaxel API. All of InB:Paxis’ products are manufactured in production facilities operating under cGMP standards and meet or exceed the USP specifications. Additional information on InB:Paxis and its products can be obtained from its website at www.paxispharma.com or by calling (303) 448-9850.
About Integrated BioPharma Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the Company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Integrated BioPharma Inc.
CONTACT: Dina Masi, CFO, Integrated BioPharma, Inc., 1-888-319-6962,d.masi@ibiopharma.com
Web site: http://www.iBioPharma.com/
